Aardvark Therapeutics Inc. has announced the dosing of the first patient in Australia as part of its Phase 3 HERO pivotal clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi syndrome $(PWS)$. Regulatory clearance for trial enrollment has also been received in Canada and the United Kingdom, with enrollment already underway in the United States and Australia. The company reports strong interest and participation from the patient community, noting that all patients who have completed the 12-week trial to date have enrolled in the Open Label Extension trial. Aardvark anticipates topline data from the HERO trial will be available in Q3 2026. No results have been presented yet.